A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication (Q44474412)

3 December 2017

A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication (English)

1 reference

3 December 2017

0 references

7

1 reference

3 December 2017

A Zullo

1

0 references

author name string

C Hassan

2

1 reference

3 December 2017

V De Francesco

3

1 reference

3 December 2017

R Lorenzetti

4

1 reference

3 December 2017

M Marignani

5

1 reference

3 December 2017

S Angeletti

6

1 reference

3 December 2017

S Morini

8

1 reference

3 December 2017

1 April 2003

1 reference

Digestive and Liver Disease

3 December 2017

1 reference

3 December 2017

35

1 reference

3 December 2017

4

1 reference

3 December 2017

232-236

1 reference

Helicobacter pylori infection, anti-cagA antibodies and peptic ulcer: a case-control study in Italy.

3 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900059-8

7 January 2021

Risk factors for cancer development in Helicobacter pylori gastritis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900059-8

7 January 2021

Gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type: management of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900059-8

7 January 2021

Rescue Therapy for Helicobacter pylori.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900059-8

7 January 2021

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900059-8

7 January 2021

Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900059-8

7 January 2021

Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900059-8

7 January 2021

Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900059-8

7 January 2021

Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900059-8

7 January 2021

Re-treatment after Helicobacter pylori eradication failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900059-8

7 January 2021

Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900059-8

7 January 2021

A triple therapy regimen after failed Helicobacter pylori treatments

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900059-8

7 January 2021

Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900059-8

7 January 2021

Cure of Helicobacter pylori-positive active duodenal ulcer patients: a double-blind, multicentre, 12-month study comparing a two-week dual vs a one-week triple therapy. GISU (Interdisciplinary Group for Ulcer Study)

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900059-8

7 January 2021

Duodenal stenosis and Helicobacter pylori.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900059-8

7 January 2021

Helicobacter pylori infection and the development of gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900059-8

7 January 2021

Helicobacter pylori eradication: do we have another ace up our sleeve?

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900059-8

7 January 2021

Treatment after failure: the problem of "non-responders".

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900059-8

7 January 2021

The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900059-8

7 January 2021

Two-day 'weekend' lansoprazole-quadruple therapy for Helicobacter pylori infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900059-8

7 January 2021

Rifabutin-based Helicobacter pylori eradication 'rescue therapy'.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900059-8

7 January 2021

Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900059-8

7 January 2021

How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients. A personal viewpoint

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900059-8

7 January 2021

Is eradication of Helicobacter pylori with colloidal bismuth subcitrate quadruple therapy safe?

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900059-8

7 January 2021

A new highly effective short-term therapy schedule for Helicobacter pylori eradication

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900059-8

7 January 2021

Two new treatment regimens for Helicobacter pylori eradication: a randomised study.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2803%2900059-8

7 January 2021

10.1016/S1590-8658(03)00059-8

Identifiers

DOI

1 reference

3 December 2017

1 reference